Perioral dermatitis is a skin condition characterized by a rash around the mouth. It is one type of dermatitis, which is a general term for skin irritation. In the word “perioral,” “peri ...

Serious infusion reactions have also occurred. Very common side effects with KEYTRUDA alone include diarrhoea, nausea, itching, rash, joint pain, back pain, feeling tired, cough, patches of ...

Merck & Co/MSD has won approval in the US for PD-1 inhibitor Keytruda as a treatment for hepatocellular carcinoma (HCC), the most common form of liver cancer, opening up another front in its ...

US pharma major Merck & Co (NYSE: MRK) has shared the first results from a late-stage trial of a subcutaneous version of its blockbuster immunotherapy Keytruda (pembrolizumab), with data presented ...

Merck (MRK) released phase III data for an injection form of its blockbuster cancer treatment drug Keytruda and announced the FDA is reviewing the application for approval. The data showed that ...

40% of Merck & Co., Inc.'s revenues are driven by cancer med Keytruda, which faces patent expiry by 2028, posing a significant risk to future earnings and share price value. The company is ...

For reasons poorly understood, the virus can suddenly reactivate, rapidly multiplying and moving toward the skin where it triggers an outbreak of painful, blistering rash. The location of the rash can ...

The US Food and Drug Administration (FDA) has granted traditional approval to Merck & Co’s (NYSE: MRK) Keytruda (pembrolizumab) with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy ...

There are concerns about Merck’s ability to successfully navigate the loss of exclusivity period for its blockbuster drug, Keytruda, and potential competition for Keytruda. With a weak fourth ...

When combined with trastuzumab and chemotherapy, treatment with pembrolizumab was associated with a statistically significant improvement in PFS and OS compared with placebo. The conversion to ...

With Keytruda, the best-selling drug in the world, facing the end of exclusivity in 2028, BioSpace looks at five drugs that have taken the leap off the patent cliff. Big Pharma is staring down the ...